Engineering Insulin-Producing Cells to Survive the Immune System

For people with Type 1 diabetes, replacing lost beta cells has long been an appealing goal. Mesenchymal stromal cells (MSCs)—a type of cell found in bone marrow and other tissues—offer a practical starting point. Scientists can coax these cells to become insulin-producing cells (IPCs), and crucially, MSCs carry natural immune-calming properties and pose lower cancer risk than some alternative sources.

But transplanting these cells is not straightforward. Once inside the body, insulin-producing cells derived from MSCs face a double threat: the immune system recognizes them as 'foreign' and attacks them, and—importantly—the autoimmune process that destroyed the patient's original beta cells can restart and destroy the new ones too.

Research shows that the transformation of MSCs into insulin-producing cells actually changes which markers appear on the cell surface—the molecular 'ID badges' the immune system uses to distinguish self from non-self. These new markers make the cells more visible to rejection.

Additionally, the cells become vulnerable to natural killer cells (immune cells that patrol for abnormal tissue) and remain at risk from the specific autoimmune response that originally attacked beta cells. Even if a transplanted cell survives initial rejection, dormant autoreactive immune memory can reawaken and attack again.

To address these obstacles, researchers are turning to CRISPR—a precise gene-editing tool—to engineer more 'immune-evasive' insulin-producing cells. The strategy involves editing the genes that control how cells present antigens (the markers that trigger immune recognition), dampening signals that attract natural killer cells, and enhancing immune checkpoint pathways that help cells resist attack.

The critical goal is to make these changes while keeping the cells' ability to produce insulin intact. Researchers are developing frameworks that combine genome editing with careful cell maturation and long-term safety testing to ensure the engineered cells work as intended.

This MSC-based approach with CRISPR engineering occupies its own translational niche compared with other advancing cell therapies for Type 1 diabetes, such as induced pluripotent stem cell (iPSC)-derived approaches. The MSC platform may offer distinct safety advantages and different immunological properties, positioning it as a complementary rather than competing strategy.

Moving this technology from the laboratory into clinical practice will require rigorous safety evaluation and demonstration that engineered cells can survive and function over the long term in the face of both alloimmune and autoimmune challenges.

Source: Stem cell reviews and reports. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.